• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

No Association Between Direct-Acting Antivirals and Hepatocellular Carcinoma Progression on the Waiting List: Time to Put This Controversy to Rest?

作者信息

John Binu V

机构信息

Department of Hepatology, Bruce W. Carter VA Medical Center, Miami, FL.

出版信息

Liver Transpl. 2020 May;26(5):621-623. doi: 10.1002/lt.25746. Epub 2020 Apr 9.

DOI:10.1002/lt.25746
PMID:32147956
Abstract
摘要

相似文献

1
No Association Between Direct-Acting Antivirals and Hepatocellular Carcinoma Progression on the Waiting List: Time to Put This Controversy to Rest?
Liver Transpl. 2020 May;26(5):621-623. doi: 10.1002/lt.25746. Epub 2020 Apr 9.
2
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Liver Transpl. 2017 Dec;23(12):1628-1629. doi: 10.1002/lt.24962.
3
Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.反对观点：使用直接抗病毒药物治疗丙型肝炎病毒：无需担忧肝细胞癌的潜在威胁。
Liver Transpl. 2017 Dec;23(12):1596-1600. doi: 10.1002/lt.24959.
4
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.因直接作用抗病毒药物治疗的丙型肝炎病毒感染患者肝癌进展而从肝移植候补名单中退出的比率。
Liver Transpl. 2017 Sep;23(9):1103-1112. doi: 10.1002/lt.24790.
5
Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.专业观点：直接作用抗病毒药物与肝细胞癌的发生和复发有关。
Liver Transpl. 2017 Dec;23(12):1593-1595. doi: 10.1002/lt.24960.
6
Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.自直接作用抗病毒治疗问世以来，英国丙型肝炎相关肝硬化和肝细胞癌的肝移植名单有所减少。
J Viral Hepat. 2019 Feb;26(2):231-235. doi: 10.1111/jvh.13022. Epub 2018 Nov 14.
7
Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.丙型肝炎相关肝细胞癌肝移植术后的直接抗病毒治疗与肿瘤复发
J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.
8
Hepatocellular carcinoma and direct-acting antivirals: A never ending story?肝细胞癌与直接作用抗病毒药物：一个永无止境的故事？
Liver Int. 2017 Jun;37(6):812-814. doi: 10.1111/liv.13421.
9
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?我们是否应该在治疗肝癌的同时治愈丙型肝炎病毒？
Liver Int. 2018 Dec;38(12):2108-2116. doi: 10.1111/liv.13918. Epub 2018 Jul 21.
10
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.